王仁敏,郭兵,任崇敏,万昌武,张凤莉,钟复光
Wang Renmin,et alDepartment of Cancer,Guiyang Medical College

• 1:贵阳医学院附院肿瘤科
• 2:贵阳医学院生物技术研究开发中心
• 3:贵阳医学院医学科学研究所

摘要(Abstract)：

白细胞介素２（ＩＬ－２）联合淋巴因子活化的杀伤细胞（ＬＡＫ细胞）胸腹腔内注入治疗癌性胸腹水１４例，总有效率７１．４２％。其中经顺铂胸腹腔内化疗无效后再改用ＩＬ－２／ＬＡＫ治疗的７例中，５例有效。癌性胸水疗效优于腹水。腔内每次注入ＩＬ－２４０～６０万Ｕ的疗效比剂量低者好。３例每次ＩＬ－２／ＬＡＫ治疗后连续３ｄ用ＩＬ－２１０～２０万Ｕ／ｄ腔内注入，利于ＬＡＫ细胞扩增，疗效满意。获ＣＲ、ＰＲ者Ｋａｒｎｏｆｓｋｙ（ＫＰＳ）评分平均提高１０～２０分。
Injection of IL-2 with LAK cells (IL2/LAK) into abdomen or thorax was used to treat ascites or hydrothorax caused by carcinomas in 14 patients and the total efficiency (CR plus PR) was 7142%.5 of 7 patients who did not react to cisplatin respondid to the treatment of IL2/LAK.This therapy was more effective to hydrothorax (8889%) than that to ascites (40%) brought about by carcinomas.Injection of 400-600 thousand units of IL2 into abdomen or thoracic cavity seemed better than that of lower doses.Continual injection of 100-200 thousand units of IL2 for 3 days following use of IL2/LAK was encouraging since this improves multiplication of LAK cells in the body.The patients who got CR or PR had 10-20 points more than those before this therapy according to KPS.Our observation showed that IL2/LAK had not any serious toxicity and side effects and it's curative effect is reliable and valuable clinically.

关键词(KeyWords)： 白细胞介素2,淋巴因子活化的杀伤细胞,癌,胸水,腹水
iuterleubin2;lymphokine activated killer cells;carcinoma;hydrothorax;ascites

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王仁敏,郭兵,任崇敏,万昌武,张凤莉,钟复光
Wang Renmin,et alDepartment of Cancer,Guiyang Medical College

Email:

DOI: 10.19367/j.cnki.1000-2707.1997.04.018

参考文献(References)：

• 1RosenbergSA，etal．Observationsonthesys－temicadministrationofaltologouslymphokike－activatedkilercelsandrecombinantinter－leukin－2topatientswithmetaslaticcancer．NEnglJMed，1985，313：14852安一明，等．肝动脉化疗栓塞结合LAK／IL－2治疗肝癌．中国肿瘤临床，1994，21（11）：8303刘旭，等．自身或同种LAK细胞联合IL－2治疗121例晚期肺癌癌性胸水的近期疗效观察．中华肿瘤杂志，1993，15（3）：204茅国新，等．基因重组白细胞介素2联合杀伤细胞治疗晚期肺癌癌性胸腔积液．中华结核和呼吸杂志，1995，18（2）：845许祥裕，等．异体LAK细胞的制备及其对恶性胸腹水的治疗作用．中华消化杂志，1991，11（1）：366蒋东霞，等．人同种异体脾LAK细胞治疗晚期恶性肿瘤的临床研究．中国肿瘤临床，1996，23（3）：194

文章评论(Comment)：